

Shared by @Mangan150 ↗

Shared by @MayoClinic ↗
Shared by @Medscape ↗
Phased review has started to accelerate assessment of medicine with potential to address high unmet medical need
Looking forward to the future, the trends and challenges regarding the increasing utilization of real-world data and single-arm trials in the oncology drug approval pathway by European Medicines Agency (EMA) is very important, especially in the context of




Shared by @Medscape ↗
Shared by @Medscape ↗




Shared by @EricTopol ↗
Shared by @Medscape ↗
Shared by @stkirsch ↗
Shared by @MayoClinic ↗